Similiar legislation died last year after getting House approval.

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Bayer Cropscience Ltd. key Products/Revenue Segments include Insecticides, Pesticides, Herbicides, Weedicides & Fungicides, Other Operating Revenue, Scrap and Royalty Income for the year ending 31-Mar ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

The pharmaceutical landscape sees movement beyond the courtroom as Biogen focuses on growth from new product launches rather than acquisitions to drive future revenues. Similarly, Bayer's ...

For the quarter ended December 31, 2024, the fund returned -8.48% compared to the MSCI World ex USA Index’s -7.43% ... Fund highlighted stocks like Bayer Aktiengesellschaft (OTC:BAYRY) in ...

The drug, developed by US pharmaceutical giant Pfizer for certain types of advanced breast cancer, was approved for sale in 2015. Pfizer said its patent on the drug is valid until 2027.